Intravitreal injection of bevacizumab for central retinal vein occlusion Setsuko Kawakami 1 , Yoshihiro Wakabayashi 1 , Naomichi Katai 2 , Tsuyoshi Agawa 1 , Kazuhiko Umazume 1 , Masaru Takeuchi 1 , Hiroshi Goto 1 1Dept of Ophthalmol,Tokyo Med Univ 2Dept of Ophthalmol,Tokyo Med Univ Hachioji Med Cent pp.1183-1186
Published Date 2010/7/15
DOI https://doi.org/10.11477/mf.1410103270
  • Abstract
  • Look Inside
  • Reference

Abstract. Purpose:To report the outcome of intravitreal injection of bevacizumab in eyes with central retinal vein occlusion(CRVO). Cases and Method:This study was made on 14 eyes of 14 patients of CRVO with macular edema. The series comprised 9 males and 5 females. The age ranged from 62 to 88 years,average 74 years. Visual acuity was expressed as logMAR. Bevacizumab was injected in the vitreous at the dosis of 1.25 mg per session. Cases were followed up for 6 months or longer. Results:Final visual acuity increased to 0.57±0.50 from the pretreatment level of 1.00±0.75. The difference was significant(p<0.05). Foveal thickness decreased from 758±179μm before treatment to 296±236μm at the last visit. The difference was significant(p<0.01). Eight eyes with foveal thickness of 700μm or over received an average of 4.9 injections. Four eyes with lesser thickness received 2.7 injections. The difference was significant(p<0.05). Conclusion:Intravitreal bevacizumab was followed by improved visual acuity in eyes with CRVO with macular edema. Severe or persistent cases needed repeat injections.

Copyright © 2010, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院